ABOUT 15th_ELSF
> REGISTRATION​
> AGENDA​
> ATTENDEES​
> INVESTORS​
> SHOWCASES
> SPONSORS
> SUPPORTERS​
​> NETWORKING​

> ABOUT LAST YEAR​

We are pleased to announce that the virtual 15th Annual European Life Sciences CEO Forum (ELSF) will take place on the 1st-2nd of March 2022 and be part of the digital Sachs Spring Life Sciences Week, that will also incorporate the 3rd Annual European HealthTech CEO Forum.

IMPORTANT UPDATE
​
Please note, due to the Omicron variant and new Swiss quarantine regime for incoming arrivals we have decided to suspend in-person registrations for the Sachs Life Science Week. Meanwhile, we will be planning the event in digital format and will provide the usual stimulating programme, company showcases, and the usual networking opportunities delivered via the video online meeting system.

Back for its 15th Annual Edition, this global bio-pharma industry event will address the main challenges for 2022, including investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors.

The main programme for the 15th Annual ELSF is spread throughout 2 days (1st-2nd of March) and will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 12 hours of high-level speeches and panel discussions. In addition, there will be 45+ presentations by globally established public, private, emerging and seed companies who offer innovation solutions and are seeking investment and partnering opportunities. We anticipate 400+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, bankers and advisors.

The virtual meetings will take place from the 28th February to 4th of March. Moreover, the system will be open for 12 hours a day and we expect 1500+ meetings completed over 5 days. The conference will be held in the Central European Time Zone. The digital event will consist of:

BioCapital & Investment Day (Tuesday, 1st of March)

• State of the Industry Panel
• Pandemic Response Panel
• VC, Private Equity Funds Panel
• Platform Technologies & Novel Therapeutics Panel
• Biotech Capital Markets Panel
• Advances in Gene & Cell Therapies Panel
• Early Stage Innovation & Investment Panel
• Rising Stars Session
  

 
Bio-Pharma Partnering & Therapeutics Day (Wednesday, 2nd of March)

• China BioPartnering & Investment: Bringing Chinese Innovation to Global Markets Panel
• Pharma M&A and Partnering Panel
• Immuno-Oncology BD & Partnering Panel
• Advances in Immuno-Oncology Panel
• Recent Advances in Alzheimer’s & Other Neurodegenerative Disorders Panel
• Biotech Meets FoodTech Panel

Online Virtual Meetings (28th February - 4th of March)

Confirmed Chairs & Speakers Include:

• Alexandre Bastos, Head of Front End Innovation, Givaudan
• Andrea Carfi, Chief Scientific Officer, Infectious Disease, Moderna, Inc.
• Andreas Hohn, Director of Transaction Excellence, Roche Partnering, F. Hoffmann-La Roche Ltd.
• Andrew Allen, Co-Founder, President & CEO, Gritstone Bio, Inc.
• Aram Mangasarian, CEO, NOXXON Pharma NV
• Bibhash Mukhopadhyay, Founder & Managing Partner, Sound Bioventures Management AB
• Christina Hertel, Senior Program Manager – Gold Track, EIT Health e.V.
• Corinne Venot, Executive Director, Business Development, BeiGene Ltd.
• Daniel Teper, Co-Founder, Chairman & CEO, Cytovia Therapeutics Inc.
• Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
• Didier Toubia, Co-Founder, CEO of Aleph Farms
• Duncan Young, Senior Director, Search & Evaluation, Oncology R&D, AstraZeneca
• Emmanuelle Coutanceau, Partner, Novo Seeds, Novo Holdings A/S
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
• Fintan Walton, Founder & CEO, PharmaVentures Ltd.
• Fiona Choppe Magal, Partner, Cukierman & Co. Investment House, FoodTech & Agritech
• Florian Schödel, Owner, Philimmune, LLC
• Gabriel Cavazos, Senior Managing Director, Investment Banking, SVB Leerink
• George Frodsham, Founder & CEO, MediSieve
• Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Jefferies International Ltd.
• Gregor Macdonald, VP, Head of BD & Licensing, Search & Assessment, H. Lundbeck A/S
• Hany Awadalla, Managing Director & Head of Investment Banking, LifeSci Capital LLC
• Hubert Birner, Managing Partner, TVM Life Science Management GmbH
• Holger Kissel, Vice President Business Alliances, BioNTech SE
• Ilan Sobel, CEO, BioHarvest Sciences Inc.
• Jan de Kerpel, Managing Director, Head of Life Sciences & Healthcare Kempen & Co
• Juan Carlos Jaramillo, Chief Medical Officer, Valneva SE
• Kaare Engkilde, CEO, Amniotics AB
• Katya Smirnyagina, Senior Partner for Life Sciences, Oxford Sciences Innovation
• Kay Penicud, Director of Innovation and Business, UK Dementia Research Institute
• Khatereh Ahmadi, Head of Search & Evaluation Business Development, Europe & Middle East, MSD
• Kylor Hua, Executive Director, Torreya
• Lynn Durham, Founder & CEO, STALICLA SA
• Marietta Wu, Managing Director, Quan Capital
• Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
• Max Herrmann, Head of UK Healthcare Equity Research, Stifel Financial Corp.
• Meredith Fisher, Partner, Mass General Brigham Ventures
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Cozart, Managing Partner, LifeSci Consulting
• Michael Friedrich, CEO, Distalmotion SA
• Michael Margolis, Senior Managing Director, Co-Head, Healthcare Investment Banking, Oppenheimer & Co. Inc
• Michael Rice, VP, Head of Advanced Therapeutics & Rare Diseases, Cello Health BioConsulting
• Miguel Forte, CEO, Bone Therapeutics SA
• Mike Romanos, Co-Founder & CEO, Microbiotica Ltd.
• Mythili Koneru, CMO, Marker Therapeutics, Inc.
• Nanna Lüneborg, General Partner, Forbion
• Narender Mantena, CEO, Biological E Limited
• Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.
• Nicholas Franco, EVP & Chief Business Development Officer, Allschwil Site Head, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson
• Nicholas Moore, Managing Director, Healthcare Investment Banking, Stifel Nicolaus Europe Limited
• Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie, Inc.
• Paul Hermant, Partner, Bird & Bird LLP
• Peter Llewellyn-Davies, CEO/CFO, invIOs GmbH
  
• Rainer Strohmenger, Managing Partner, Wellington Partners Life Sciences (WPLS)
• Reagan Jarvis, CEO, Anocca AB
• Renee Aguiar-Lucander, CEO, Calliditas Therapeutics AB
• Robert de Jonge, VP Head of Corporate Development, Mestag Therapeutics Ltd.
• Ros Deegan, CEO, OMass Therapeutics
• Ryan Richardson, Chief Strategy Officer, BioNTech SE
• Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence
• Sascha Berger, General Partner, TVM Life Science Management GmbH
• Sandra Ferri, Head of Life Sciences Investments, European Investment Fund
• Sarah Holland, CBO, VectivBio AG
• Shafique Virani, Chief Corporate Development Officer, Recursion, Inc.
• Søren Møller, Managing Partner, Novo Holdings A/S
• Speaker TBA, BeiGene Ltd.
• Stephanie Léouzon, Partner & Head of Europe, Torreya
• Stephen Myatt, CEO, Macomics Ltd.
• Steve Rees, Vice President of Discovery Biology, AstraZeneca
• Theodora Harold, CEO, Crescendo Biologics Ltd.
• Thibaut Roulon, Senior Investment Director, Bpifrance
• Thijs Cohen Tervaert, Junior Partner, INKEF Capital BV
• Thomas Roth, CEO, Inzipio GmbH
• Thomas Shrader, Managing Director & Healthcare Analyst, BTIG, LLC
• Tim Dyer, Co-Founder, Board Director & CEO, Addex Therapeutics Ltd.
• Tim Haines, Chairman & Managing Partner, Abingworth LLP
• Tim Luker, VP Venture Science, Corp BD, Eli Lilly and Company
• Volker Germaschewski, SVP R&D, eTheRNA immunotherapies NV
• Yonatan Golan, CEO, Brevel Ltd.
• More TBA...

SPOTLIGHT SHOWCASES:

Showcases Include:

PARTICIPATION OPTIONS INCLUDE

Free access to view live sessions is provided to all interested and qualified participants, this will allow us to provide a higher exposure for participating companies. Additionally, you can purchase a Video on Demand pass, which will allow you to view not only live sessions, but also recordings of all sessions, in addition to speaker and company profiles and their presentations.
 
The Online Meeting System will open on the 14th of February for uploading profiles and sending meeting invites. Meetings will take place from the 28th February to 4th of March. The system will allow you to have a secure audio/video call, as well as an option to present slides using the screen share function. Meetings will last for 30 minutes. The Basic Online Meeting System Access, with 10 meeting invitations, will be provided complimentary for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however organizer has the discretion to reject passes. Other participants may consider purchasing Basic, Advanced or Premium Access with an option for a live spotlight or a pre-recorded showcase presentation. The number of meeting invites defines how many requests can be sent. If a meeting invite is declined, you will receive a meeting credit back that can be reused. The number of invites does not restrict how many meeting invitations you can receive.
​
If we are permitted to deliver a hybrid event you will have an option to register and attend two days in-person, which will include a mix of live content, which will be broadcasted, and pre-recorded content streamed live, in addition to pre-arranged in-person & virtual meetings and a reception. More information and option will be announced in January.

PRESENTING OPPORTUNITIES: 

Gain additional exposure to high-level decision makers by presenting at the forum, which offers excellent opportunities to showcase your company’s investment and partnering offering. This typically includes technology and financial highlights. This adds to the news flow from the forum and generates greater interest in meetings from other delegates.
 
​For those interested to join the companies’ showcases, there is an option to purchase either a 10 or 20 minute presentation, which will be pre-recorded in advance and available to all registered attendees before, during and after the conference on the event’s portal. There is also a limited number of 20-minute Spotlight presentations with additional branding to provide even higher exposure, which will be broadcasted live during the main programme after a relevant panel discussion and available on demand afterwards. Start-up companies, which are looking for seed financing may also apply for a 5 or 10 minute showcase option. The Sachs team can assist with the pre-recording of the presentation or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.

EXHIBITING OPPORTUNITIES: 

Make connections, engage in conversation, and exchange knowledge with key decision-makers, who are eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at Sachs Spring Life Sciences Week is an effective way to gain leads, introduce new products and services, expand sales and build relationships.
 
The virtual exhibition package includes a dedicated virtual page, where we can: upload your branded company’s profile; list ways to reach you; share video or images about services you provide; have files ready for download, if you wish to share any additional information with potential clients.

SPONSORING OPPORTUNITIES: 

There are a limited number of sponsorship opportunities for the forum, which includes speaking, advertising and branding options. Sponsors typically include investment banks and funds, large pharma, technology companies and service providers, including Stock Exchanges, IR companies, CROs, international lawyers and consulting companies. Tailored packages are available upon request. You can view latest event’s sponsors here.

To learn more about presenting, exhibition or sponsorship opportunities, please fill in registration form or contact us at SachsTeam@SachsForum.com or by phone + 44 (0)203 463 4890.

Silver Sponsors:

---

Bronze Sponsor:

---

Contributing Sponsors:

---

Supporters:

---

Participating Pharmas:

---

Investors & Analysts attending:

3B Future Health Ventures
6 Dimensions Capital
Abingworth LLP
Additio Investment Group
Aescuvest International
Aglaia Oncology Funds
Allele Capital Partners
Alpha Blue Ocean Ltd.
ALSA Ventures
Amadeus Capital Partners
Apeiron Investments
Apollo Health Ventures
Aqua Partners LLC
ARCH Venture Partners
Arix Bioscience plc
Asabys Partners
Ascend Capital Partners
Asklepios Advisors
ATGN Consulting
ATP (Apple Tree Partners)
AurorA Science Srl
AVANTECA Partners AG
BaseLaunch
Bergmann zur Hausen & Cie. GmbH
BERNINA BioInvest Ltd.
Big Pi Ventures SCSp
BIMA Capital, LLC
Bio Medi Gene Ventures
BioMedPartners AG
Bionova Capital SCR SA
BioPharma Advisory
Bioqube Ventures
BIOSTART Consulting GmbH
BioValley Basel & Suterscience, LLC
BioVeda China Fund (BVCF)
Bootstrap Europe SCSP
Bpifrance
Bradley Woods & Co. Ltd
Brandon Capital Partners
Breslin AG
Brightlands Venture Partners
Brookline Capital Markets
BROTHERS & Partners Europe
BTIG, LLC
Caixa Capital Risc
Catalytic Impact Foundation, Inc.
Cello Health BioConsulting
Claris Ventures
Clave Mayor S.G.E.I.C., S.A.
coparion GmbH & Co. KG
CTI Life Sciences
Cukierman & Co. Investment House, FoodTech & Agritech
Cukierman & Co. Life Sciences
Debiopharm Innovation Fund SA
Deep Science Ventures
Deutsche Bank
Digital Networks PLC
Dorset Capital LLC
Droege Group
E.Gutzwiller & Cie, Banquiers
Eight Roads Ventures
Eir Ventures Partners AB
Epidarex Exeed Limited
ESC Advisors
European Investment Fund
Ferghana Partners LLP
Flerie Invest AB
Forbion
Forty51 Ventures
Fountain Healthcare Partners Ltd
Fraser Finance LLP
FutuRx Ltd.
GCF Family Office
GEM
Generation Fund Life Sciences Fund I
Gimv NV
Global Founders Capital
Global Health Investment Corporation
GLSV GmbH iL | MicroCures Inc | Neurevo GmbH
Hadean Ventures
HBM Partners AG
HealthCap
HealthCare Royalty Partners
Hestia Investments Ltd.
High-Tech Gründerfonds Management GmbH
IAG - Italian Angels for Growth
IAG, Image Analysis Group
IBB Beteiligungsgesellschaft GmbH
ICF Consult Switzerland
Illumina Ventures
Inbio Ventures
Indaco Venture Partners SGR SpA
Independent R.B.
Independent R.M.
Industrifonden
INKEF Capital BV
Inveready Asset Management
Invivo Capital Partners, S.G.E.I.C, S.A.
IPF Partners
J.P. Morgan
Jefferies International Ltd.
Jeito Capital
Johnson & Johnson Innovation – JJDC, Inc.
Kempen & Co
KIZOO Technology Capital GmbH
Kreos Capital
Kurma Partners
Landmark Angels, Inc.
Landmark BioVentures AG
LifeArc Ventures
LifeCare Partners GmbH
LifeLink Ventures
LifeSci Capital LLC
LifeSci Consulting
Long State Investments
Longliv Ventures
LSFA & BRESLIN AG

To View All - Click Here